Àá½Ã¸¸ ±â´Ù·Á ÁÖ¼¼¿ä. ·ÎµùÁßÀÔ´Ï´Ù.

Àü¸³¼±ºñ´ëÁõ Áø´Ü¿¡¼­ ÀÌÇà´ë ¿ëÀûÁö¼ö (Transition Zone Index)ÀÇ À¯¿ë¼º; Áõ»óÁ¡¼ö ¹× ¿ä·ù¼Óµµ¿ÍÀÇ »ó°ü°ü°è Usefulness of Transition Zone Index in Assessing Benign Prostatic Hyperplasia: Correlation with Symptom Score and Uroflow

´ëÇѺñ´¢±â°úÇÐȸÁö 1998³â 39±Ç 11È£ p.1098 ~ 1103
½É°­¼ö, ¹ÚÈì·Ê,
¼Ò¼Ó »ó¼¼Á¤º¸
½É°­¼ö (  ) 
°í·Á´ëÇб³ »ý¹°Çаú

¹ÚÈì·Ê (  ) 
°í·Á´ëÇб³ ÀÇ°ú´ëÇÐ ºñ´¢±â°úÇб³½Ç

Abstract

¼­·Ð
Àü¸³¼±ºñ´ëÁõ(ÀÌÇÏ BPH)ȯÀÚ¿¡ À־ Àü¸³¼± ÀýÁ¦¼ú ¹× ¾à¹°Ä¡·á¸¦ ½ÃÇàÇÏ°íÀÚ ÇÒ ¶§
Àü¸³¼±ÀÇ Å©±â¸¦ ÃøÁ¤ÇÏ´Â °ÍÀº Ä¡·á¹æħÀÇ °áÁ¤¿¡ Áß¿äÇÑ ÀÎÀÚ·Î ÀÛ¿ëÇÑ´Ù. ±×·¯³ª Á÷Àå¼ö
Áö°Ë»ç³ª ¹æ±¤°æ, ¿ªÇ༺¿äµµÁ¶¿µ¼úÀº Àü¸³¼±ÀÌ ¸Å¿ì Å« °æ¿ì, Àü¸³¼± Å©±â¸¦ ÃøÁ¤Çϴµ¥ ¿À
Â÷°¡ »ý±æ ¼ö ÀÖ´Ù. ÇöÀç·Î¼­ Àü¸³¼± Å©±â¸¦ ÃøÁ¤Çϴµ¥ À־ °¡Àå À¯¿ëÇÑ Áø´Üµµ±¸´Â °æ
Á÷ÀåÃÊÀ½ÆÄ°Ë»ç·Î ¾Ë·ÁÁ® ÀÖ´Ù. ÇÑÆí ¿©·¯ ÀúÀÚµéÀº Àü¸³¼±ÀÇ Å©±â¿Í, Àü¸³¼±ÁõÀ» Æò°¡ÇÏ´Â
´Ù¸¥ ÁöÇ¥µéÀÎ Áõ»óÁ¡¼ö ÃÖ°í¿ä¼Ó, ÀÜ´¢·®°úÀÇ ¿¬°ü¼ºÀº ³ôÁö ¾ÊÀº °ÍÀ¸·Î º¸°íÇÏ°í ÀÖ´Ù.
ÀÌ·± ³·Àº »ó°ü°ü°è´Â ºÎºÐÀûÀ¸·Î´Â Àü¸³¼± ¿ëÀûÀÇ ÃøÁ¤¿¡¼­ÀÇ ¿À·ù¿¡ ÀÇÇÒ ¼ö°¡ ÀÖ´Ù. Àü
¸³¼±ºñ´ëÁõÀº ÀÌÇà´ë(transition zone)ÀÇ °úÁõ½ÄÀ¸·Î ÀÎÇÑ ÀÌÂ÷ÀûÀÎ °á°ú·Î¼­ Á߽ɴë(central
zone)³ª ¿äµµÁÖÀ§¼±(penuretbral gland)°ú´Â ºñ±³Àû °ü°è°¡ Àû´Ù. TewanµîÀº finasteride¸¦
Åõ¿© ÈÄ ÀÌÇà´ë ¿ëÀûÀÇ °¨¼Ò°¡ µÎµå·¯Á³À¸¸ç, Àü¸³¼±ÀÇ ÀÌÇà´ë¿ëÀû·üÀ̳ª ÀÌÇà´ë¿ëÀûÀÇ °¨
¼Ò°¡ ¿ä·ù¼Óµµ Áõ°¡¿Í ¸Å¿ì ¹ÐÁ¢ÇÑ °ü°è¿¡ ÀÖ´Ù°í º¸°íÇÏ¿´À¸¸ç, Kaplan µîµµ ÀÌÇà´ë¿ëÀû·ü
ÀÌ Àüü Àü¸³¼±¿ëÀûº¸´Ù ȯÀÚÀÇ Áõ»óÀ̳ª ¿ä·ù¼Óµµµî°ú ¹ÐÁ¢ÇÑ ¿¬°üÀ» º¸¿´´Ù°í ÇÏ¿´´Ù. ¹Ý
¸é¿¡ LeporµîÀº Àü¸³¼±ÀÌÇà´ë¿ëÀûÀ̳ª ÀÌÇà´ë¿ëÀû·ü°ú ¿ä·ù¼Óµµ ¹× Áõ»ó Á¡¼ö¿ÍÀÇ ¿¬°üÀÌ
³·´Ù´Â »ó¹ÝµÈ °á°ú¸¦ º¸°íÇÏ¿´´Ù. µû¶ó¼­ ÀúÀÚµéÀº ÀÌÇà´ë¿ëÀû°ú Àüü¿ëÀû ´ëºñ ÀÌÇà´ë ¿ë
Àû·üÀ» ÃøÁ¤ÇÏ´Â °ÍÀÌ Àü¸³¼±ºñ´ëÁõÀ» Áø´ÜÇϴµ¥ À¯¿ëÇÑÁö, ¶ÇÇÑ Áõ»óÁ¡¼ö(IPSS)³ª ÃÖ°í¿ä
¼Ó, ÀÜ´¢·®°ú ¹ÐÁ¢ÇÑ ¿¬°ü¼ºÀÌ ÀÖ´ÂÁö¸¦ ¾Ë¾Æº¸°íÀÚ ÇÏ¿´´Ù.

Purpose: Prostate volume has been known to be poorly correlated with other
parameters used to assess benign prostatic hyperplasia(BPH), including symptom score,
peak flow rate(Qmax), amount of postvoid residuals(PVR). The purpose of this study
was to determine if measurement of the transition zone index(TZI) of the prostate
correlated well with other clinical parameters in predicting the degrees of obstruction.
Materials and Methods: We prospectively evaluated 86 men with symptomatic
BPH(mean age: 65.4 years) according to symptoms, Qmax, PVR, transrectal ultrasound
volume of the entire prostate and the transition zone. TZI was determined as the ratio
between transition zone volume(TZV) and total prostate 1 volume(TV).
Results: Age correlated with symptoms(r=0.29, p=0.006) and PVR(r=0.466, p=0.001);
Qmax negatively correlated with age(r=-0.487, p=0.001), symptoms 1 (r=-0.28, p=0.007)
and PVR(r=-0.36, p=0.001). Age also correlated with TV(r=0.4, p=0.001), TZV(r=0.435,
p=0.001) and, TZI(r=0.36, p=0.001). There was a weak correlations between TV and
symptom r=0.23), Qmax(r=0.28), and PVR(r=0.24); a stronger correlation were noted
between TZ and symptoms(r=0.33), Qmax(r=-0.35) or PVR(r=0.28). There were
significant correlation between TZI and symptoms(r=0.35), Qmax(r=-0.38) or
PVR(r=0.30). Age, PVR, 721, and TZV were significantly greater and Qmax were
significantly lower in severe (IPSS¡Ã20, N=38) symptom group than in moderate(IPSS¡Â
19, N=48) one. (p¡Â0.01). On the other hand, the age, PVR, symptom score, TZI, and
TZV in low Qmax(¡Â10ml/sec) group were significantly greater than in high Qmax (¡Ã
15m1/sec) group. No significant differences of TV were noted either between moderate
and severe symptom group or low and high Qmax group.
Conclusions: Transition zone volume or index are parameters that correlates
significantly with evaluated parameters of BPH and may serve as a useful method for
evaluating obstruction. Studies are underway to determine if transition zone index can
be used prospectively to predict and correlate response with therapies designed to ablate
prostatic tissue medically or surgically.

Å°¿öµå

Benign prostatic hyperplasia; Transition zone index;

¿ø¹® ¹× ¸µÅ©¾Æ¿ô Á¤º¸

   

µîÀçÀú³Î Á¤º¸

KCI
KoreaMed
KAMS